Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study.

@article{Miyasaka2009EfficacyAS,
  title={Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study.},
  author={Nobuyuki Miyasaka and Shinichi Kawai and Hiroshi Hashimoto},
  journal={Modern rheumatology},
  year={2009},
  volume={19 6},
  pages={606-15}
}
We evaluated the efficacy and safety of tacrolimus in patients receiving glucocorticoid therapy for lupus nephritis. Patients with persistent nephritis were randomized to receive 28 weeks of double-blind treatment with tacrolimus (3 mg/day) or placebo. The primary endpoint was the change in the lupus nephritis disease activity index (LNDAI) calculated from scores for daily urinary protein excretion, urinary red cells, serum creatinine, anti-double-stranded DNA antibody, and serum complement… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…